BrainChip (BRN) Q4 2026 earnings summary

Executive summary

• Ended the quarter with a cash balance of $20.3M, down from $25.3M in the prior quarter.

• Received first production batch of 2,000 AKD1500 neuromorphic processors, marking transition to commercial-scale manufacturing.

• Expiration of LDA Put Option Agreement, with obligations settled through share liquidation.

• Advanced commercialisation strategy via new agreements, ecosystem expansion, and reference platform launches.

Financial highlights

• Net operating cash outflows were $4.7M, an improvement from $5.3M in the prior quarter.

• Receipts from customers totaled $0.15M, down from $0.7M in the previous quarter.

• Payments to suppliers and employees were $5.1M, down from $6.1M in the prior quarter.

• Cash and cash equivalents at quarter end were $20.3M.

• Estimated quarters of funding available: 4.43.

Outlook and guidance

• Anticipates commercial shipments of AKD1500 beginning in the second half of 2026.

• Focus remains on scaling commercialisation, expanding customer and partner ecosystem, and building recurring revenue through silicon sales, IP licensing, and royalties.

• AKD2500 project remains on schedule for early December tapeout.

• Internal demonstrations of the Generative AI platform expected in late Q3 2026.